Table of Contents
Molecular Biology International
Volume 2011 (2011), Article ID 854626, 10 pages
http://dx.doi.org/10.4061/2011/854626
Research Article

Peptide Inhibition of Topoisomerase IB from Plasmodium falciparum

1Department of Molecular Biology and Interdisciplinary Nanoscience Center (iNANO), Aarhus University, C.F. Møllers Allé 3, Building 1130, 8000 Aarhus C, Denmark
2Department of Biology and Center of Biostatistics and Bioinformatics, University of Rome “Tor Vergata”, Via della Ricerca Scientifica 1, 00133 Rome, Italy
3Interuniversity Consortium, National Institute Biostructure and Biosystems (I.N.B.B.), 00136 Rome, Italy

Received 1 December 2010; Accepted 3 March 2011

Academic Editor: Hemanta K. Majumder

Copyright © 2011 Amit Roy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. García-Estrada, C. F. Prada, C. Fernández-Rubio, F. Rojo-Vázquez, and R. Balaña-Fouce, “DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery,” Proceedings of the Royal Society B, vol. 277, no. 1689, pp. 1777–1787, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. R. Docampo, “Sensitivity of parasites to free radical damage by antiparasitic drugs,” Chemico-Biological Interactions, vol. 73, no. 1, pp. 1–27, 1990. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Mpia and J. Pépin, “Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis,” Tropical Medicine and International Health, vol. 7, no. 9, pp. 775–779, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Legros, G. Ollivier, M. Gastellu-Etchegorry et al., “Treatment of human African trypanosomiasis—present situation and needs for research and development,” Lancet Infectious Diseases, vol. 2, no. 7, pp. 437–440, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. S. L. Croft and G. H. Coombs, “Leishmaniasis—current chemotherapy and recent advances in the search for novel drugs,” Trends in Parasitology, vol. 19, no. 11, pp. 502–508, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Winstanley and S. Ward, “Malaria chemotherapy,” Advances in Parasitology, vol. 61, pp. 47–76, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. T. Mita, K. Tanabe, and K. Kita, “Spread and evolution of Plasmodium falciparum drug resistance,” Parasitology International, vol. 58, no. 3, pp. 201–209, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. S. L. Croft, S. Sundar, and A. H. Fairlamb, “Drug resistance in leishmaniasis,” Clinical Microbiology Reviews, vol. 19, no. 1, pp. 111–126, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. S. Gehrig and T. Efferth, “Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products,” International Journal of Molecular Medicine, vol. 22, no. 4, pp. 411–419, 2008. View at Google Scholar
  10. S. K. Singh, K. Maithal, H. Balaram, and P. Balaram, “Synthetic peptides as inactivators of multimeric enzymes: inhibition of Plasmodium falciparum triosephosphate isomerase by interface peptides,” FEBS Letters, vol. 501, no. 1, pp. 19–23, 2001. View at Google Scholar
  11. R. M. Reguera, C.M. Redondo, R. Gutierrez de Prado, Y. Pérez-Pertejo, and R. Balaña-Fouce, “DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy,” Biochimica et Biophysica Acta, vol. 1759, no. 3-4, pp. 117–194, 2006. View at Google Scholar
  12. Y. Pommier, “Topoisomerase I inhibitors: camptothecins and beyond,” Nature Reviews Cancer, vol. 6, no. 10, pp. 789–802, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. C. Wang, “DNA topoisomerases,” Annual Review of Biochemistry, vol. 65, pp. 635–692, 1996. View at Google Scholar · View at Scopus
  14. K. D. Corbett and J. M. Berger, “Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases,” Annual Review of Biophysics and Biomolecular Structure, vol. 33, pp. 95–118, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. A. Bergerat, D. Gadelle, and P. Forterre, “Purification of a DNA topoisomerase II from the hyperthermophilic archaeon Sulfolobus shibatae. A thermostable enzyme with both bacterial and eucaryal features,” The Journal of Biological Chemistry, vol. 269, no. 44, pp. 27663–27669, 1994. View at Google Scholar · View at Scopus
  16. L. A. Mitscher, “Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents,” Chemical Reviews, vol. 105, no. 2, pp. 559–592, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. A. Maxwell, “DNA gyrase as a drug target,” Trends in Microbiology, vol. 5, no. 3, pp. 102–109, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. A. M. Wilstermann and N. Osheroff, “Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes,” Current Topics in Medicinal Chemistry, vol. 3, no. 3, pp. 321–338, 2003. View at Google Scholar · View at Scopus
  19. A. Roy, B. B. Das, A. Ganguly et al., “An insight into the mechanism of inhibition of unusual bi-subunit topoisomerase I from Leishmania donovani by 3,3-di-indolylmethane, a novel DNA topoisomerase I poison with a strong binding affinity to the enzyme,” Biochemical Journal, vol. 409, no. 2, pp. 611–622, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. R. P. Bakshi and T. A. Shapiro, “DNA topoisomerases as targets for antiprotozoal therapy,” Mini Reviews in Medicinal Chemistry, vol. 3, no. 6, pp. 597–608, 2003. View at Google Scholar · View at Scopus
  21. G. I. McFadden and D. S. Roos, “Apicomplexan plastids as drug targets,” Trends in Microbiology, vol. 7, no. 8, pp. 328–333, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. E. L. Dahl and P. J. Rosenthal, “Apicoplast translation, transcription and genome replication: targets for antimalarial antibiotics,” Trends in Parasitology, vol. 24, no. 6, pp. 279–284, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. C. D. Pond, K. M. Marshall, and L. R. Barrows, “Indentification of a small topoisomerase I-binding peptide that has synergistic antitumor activity with 9-aminocamptothecin,” Molecular Cancer Therapeutics, vol. 5, no. 3, pp. 739–745, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. S. Lien and H. B. Lowman, “Therapeutic peptides,” Trends in Biotechnology, vol. 21, no. 12, pp. 556–562, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Meloen, P. Timmerman, and H. Langedijk, “Bioactive peptides based on diversity libraries, supramolecular chemistry and rational design: a new class of peptide drugs. Introduction,” Molecular Diversity, vol. 8, no. 2, pp. 57–59, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Otvos Jr., “Peptide-based drug design: here and now,” Methods in Molecular Biology, vol. 494, pp. 1–8, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. P. W. Latham, “Therapeutic peptides revisited,” Nature Biotechnology, vol. 17, no. 8, pp. 755–757, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. U. H. Manjunatha, S. Mahadevan, S. S. Visweswariah, and V. Nagaraja, “Monoclonal antibodies to mycobacterial DNA gyrase A inhibit DNA supercoiling activity,” European Journal of Biochemistry, vol. 268, no. 7, pp. 2038–2046, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. U. H. Manjunatha, A. Maxwell, and V. Nagaraja, “A monoclonal antibody that inhibits mycobacterial DNA gyrase by a novel mechanism,” Nucleic Acids Research, vol. 33, no. 10, pp. 3085–3094, 2005. View at Google Scholar
  30. M. N. Leelaram, N. Suneetha, V. Nagaraja, and R. Manjunath, “A new ELISA plate based microtiter well assay for mycobacterial topoisomerase I for the direct screening of enzyme inhibitory monoclonal antibody supernatants,” Journal of Immunological Methods, vol. 357, no. 1-2, pp. 26–32, 2010. View at Google Scholar
  31. R. Binétruy-Tournaire, C. Demangel, B. Malavaud et al., “Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis,” The EMBO Journal, vol. 19, no. 7, pp. 1525–1533, 2000. View at Google Scholar
  32. C. Monnet, D. Laune, J. Laroche-Traineau et al., “Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells,” The Journal of Biological Chemistry, vol. 274, no. 6, pp. 3789–3796, 1999. View at Google Scholar
  33. M. Zanetti, G. Filaci, R. H. Lee et al., “Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif,” EMBO Journal, vol. 12, no. 11, pp. 4375–4384, 1993. View at Google Scholar · View at Scopus
  34. G. Antoni, R. Presentini, F. Perin et al., “A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity,” Journal of Immunology, vol. 137, no. 10, pp. 3201–3204, 1986. View at Google Scholar
  35. G. Cassell, M. Klemm, C. Pinilla, and A. Segall, “Dissection of bacteriophage lambda site-specific recombination using synthetic peptide,” Journal of Molecular Biology, vol. 299, no. 5, pp. 1193–1202, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. K. Ghosh, C. K. Lau, F. Guo, A. M. Segall, and G. D. Van Duyne, “Peptide trapping of the holliday junction intermediate in Cre-loxP site-specific recombination,” The Journal of Biological Chemistry, vol. 280, no. 9, pp. 8290–8299, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. J. J. Champoux, “DNA topoisomerases: structure, function, and mechanism,” Annual Review of Biochemistry, vol. 70, pp. 369–413, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. S. G. Hansen, R. Frøhlich, and B. R. Knudsen, “Type IB topoisomerases and tyrosine recombinases—distinct functions within related structural frameworks,” Current Topics in Biochemical Research, vol. 5, pp. 149–159, 2003. View at Google Scholar
  39. M. Klemm, C. Cheng, G. Cassell, S. Shuman, and A. M. Segall, “Peptide inhibitors of DNA cleavage by tyrosine recombinases and topoisomerases,” Journal of Molecular Biology, vol. 299, no. 5, pp. 1203–1216, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. D. F. Fujimoto, C. Pinilla, and A. M. Segall, “New peptide inhibitors of type IB topoisomerases: similarities and differences vis-a-vis inhibitors of tyrosine recombinases,” Journal of Molecular Biology, vol. 363, no. 5, pp. 891–907, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. C. Aurrecoechea, J. Brestelli, B. P. Brunk et al., “PlasmoDB: a functional genomic database for malaria parasites,” Nucleic Acids Research, vol. 37, no. 1, pp. D539–D543, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. M. Lisby, J. R. Olesen, C. Skouboe et al., “Residues within the N-terminal domain of human topoisomerase I play a direct role in relaxation,” The Journal of Biological Chemistry, vol. 276, no. 23, pp. 20220–20227, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. P. Fiorani, A. Bruselles, M. Falconi, G. Chillemi, A. Desideri, and P. Benedetti, “Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I,” The Journal of Biological Chemistry, vol. 278, no. 44, pp. 43268–43275, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. K. Arnold, L. Bordoli, J. Kopp, and T. Schwede, “The SWISS-MODEL Workspace: a web-based environment for protein structure homology modelling,” Bioinformatics, vol. 22, no. 2, pp. 195–201, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. M. R. Redinbo, L. Stewart, P. Kuhn, J. J. Champoux, and W. G. J. Hol, “Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA,” Science, vol. 279, no. 5356, pp. 1504–1513, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. B. L. Staker, K. Hjerrild, M. D. Feese, C. A. Behnke, A. B. Burgin, and L. Stewart, “The mechanism of topoisomerase I poisoning by a camptothecin analog,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15387–15392, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. C. Notredame, D. G. Higgins, and J. Heringa, “T-coffee: a novel method for fast and accurate multiple sequence alignment,” Journal of Molecular Biology, vol. 302, no. 1, pp. 205–217, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. M. J. D. Powell, “An efficient method for finding the minimum of a function of several variables without calculating derivatives,” The Computer Journal, vol. 7, no. 2, pp. 155–162, 1964. View at Google Scholar
  49. B. Hess, C. Kutzner, D. van der Spoel, and E. Lindahl, “GRGMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation,” Journal of Chemical Theory and Computation, vol. 4, no. 3, pp. 435–447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. G. M. Morris, H. Ruth, W. Lindstrom et al., “AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility,” Journal of Computational Chemistry, vol. 30, no. 16, pp. 2785–2791, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. G. M. Morris, D. S. Goodsell, R. S. Halliday et al., “Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function,” Journal of Computational Chemistry, vol. 19, no. 14, pp. 1639–1662, 1998. View at Google Scholar · View at Scopus
  52. E. Lindahl, B. Hess, and D. van der Spoel, “GROMACS 3.0: a package for molecular simulation and trajectory analysis,” Journal of Molecular Modeling, vol. 7, no. 8, pp. 306–317, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. W. Humphrey, A. Dalke, and K. Schulten, “VMD: visual molecular dynamics,” Journal of Molecular Graphics, vol. 14, no. 1, pp. 33–38, 1996. View at Publisher · View at Google Scholar · View at Scopus
  54. K. Christiansen, A. B. Svejstrup, A. H. Andersen, and O. Westergaard, “Eukaryotic topoisomerase I-mediated cleavage requires bipartite DNA interaction. Cleavage of DNA substrates containing strand interruptions implicates a role for topoisomerase I in illegitimate recombination,” The Journal of Biological Chemistry, vol. 268, no. 13, pp. 9690–9701, 1993. View at Google Scholar · View at Scopus
  55. S. L. Cobb and P. W. Denny, “Antimicrobial peptides for leishmaniasis,” Current Opinion in Investigational Drugs, vol. 11, no. 8, pp. 868–875, 2010. View at Google Scholar
  56. B. L. Staker, M. D. Feese, M. Cushman et al., “Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex,” Journal of Medicinal Chemistry, vol. 48, no. 7, pp. 2336–2345, 2005. View at Publisher · View at Google Scholar · View at PubMed
  57. L. R. Haines, J. M. Thomas, A. M. Jackson et al., “Killing of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18,” PLoS Neglected Tropical Diseases, vol. 3, no. 2, article e373, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. K. S. Harris, J. L. Casey, A. M. Coley et al., “Rapid optimization of a peptide inhibitor of malaria parasite invasion by comprehensive N-methyl scanning,” The Journal of Biological Chemistry, vol. 284, no. 14, pp. 9361–9371, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. S. Pillarisetti, “Are peptide therapeutics the future?” Current Pharmaceutical Biotechnology, vol. 7, no. 4, pp. 225–227, 2006. View at Publisher · View at Google Scholar · View at Scopus